Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Researcher Urges Stem Cell Trials In U.S. Instead Of China

This article was originally published in PharmAsia News

Executive Summary

A U.S. stem cell researcher is calling on fellow scientists to conduct their clinical trials in the United States instead of China. Wise Young of Rutgers University, who once began five clinical trials in China, told a conference he changed his mind about trials there when he discovered that some Americans had wanted to be in the trial so much they volunteered to go to China to be in them. Young urged U.S. trials even though he acknowledged they were cheaper to conduct in China. The problem, he said, was there is no source of funding for U.S. trials. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel